GLP-1 and HRT Together: What the 2025 Mayo Trial Showed About Stacking Them

Women who have put in the effort to get hormone replacement therapy right know the process well: finding a provider who takes perimenopausal symptoms seriously, working through the diagnosis, and titrating to a stable regimen. For many women who complete that process, the vasomotor symptoms improve, sleep stabilizes, and cognitive symptoms clear substantially once estrogen is restored. The midsection, in most cases, does not follow suit on its own.

This is not a sign that the HRT was prescribed incorrectly or that something is being overlooked. Hormone replacement therapy was designed to address vasomotor symptoms, bone density, genitourinary atrophy, and for eligible women, cardiovascular risk. It was never designed to reverse the weight that accumulated during estrogen decline, nor to restore a metabolic rate that estrogen previously helped sustain. What HRT does accomplish is restore the hormonal environment in which the body can respond more effectively to additional interventions, including GLP-1 receptor agonists.

A 2025 Mayo Clinic retrospective analysis put population level numbers on exactly this combination. The findings are the clearest clinical signal yet that adding GLP-1 to an established HRT regimen produces meaningfully more weight loss than GLP-1 alone, and the mechanistic basis for that difference is well understood.

What the Mayo Study Actually Showed

The Mayo Clinic retrospective analysis compared outcomes in women prescribed tirzepatide (the active ingredient in Mounjaro and Zepbound) with and without concurrent hormone replacement therapy. At 18 months, women on tirzepatide alone averaged 14.2% of baseline body weight lost, while women on tirzepatide plus HRT averaged 17.3%. The difference was statistically significant.

The three percentage point gap may seem modest, but applied to a woman starting at 180 pounds, it represents approximately 5.4 additional pounds lost over 18 months, roughly 30% more total weight loss on the combined protocol than on tirzepatide alone.

Because this was retrospective and not a randomized trial, causation is not established. Women on HRT may have differed from those not on HRT in ways that the statistical adjustment for age, baseline BMI, and comorbidities did not fully capture. The design limitation stands and should be acknowledged. What the data does suggest is that the combination is not merely safe but appears to be additive for the weight outcome that most women in this clinical situation are primarily seeking.

This finding aligns with what mechanistic research has indicated for years: estrogen influences fat distribution patterns, insulin sensitivity, and muscle retention during weight loss. Restoring estrogen does not directly reverse accumulated weight, but it restores the physiological conditions under which weight loss becomes more effective.

Why HRT Alone Does Not Move the Midsection

Women often enter perimenopause care with the expectation that HRT will accomplish more than the evidence supports for body weight. That expectation is reasonable, since the improvement in other symptoms can be profound when estrogen is adequately restored, and it is natural to assume that the metabolic effects will follow.

HRT, well prescribed, reliably addresses vasomotor symptoms, sleep disrupted by cortisol and temperature dysregulation, genitourinary syndrome of menopause, bone mineral density over time, and cognitive symptoms in women who begin treatment close to menopause onset. What it addresses less reliably is weight that has already accumulated, waist circumference that expanded during the period of estrogen decline, and the metabolic rate that estrogen previously helped to sustain.

The midsection weight gain common to perimenopause is driven by the loss of estrogen's protective influence on fat distribution. When estrogen falls, fat preferentially deposits in the visceral compartment rather than subcutaneous and gluteofemoral tissue, insulin sensitivity worsens, and lean mass begins to decline. HRT restores that protective influence going forward, but it does not remove fat that has already redistributed. A woman who gains 15 pounds in her early 40s and begins HRT at 47 will typically find that new accumulation slows or stops, and that body composition may improve somewhat as visceral fat responds to restored estrogen signaling. The previously gained weight, however, generally requires a separate and targeted intervention to address.

Why GLP-1 Works Differently in Estrogen Replete Women

GLP-1 receptor agonists act on appetite regulation, satiety signaling, gastric emptying, and insulin secretion that responds in proportion to blood glucose levels. None of these mechanisms are directly estrogen dependent at the receptor level. A woman in deep estrogen deficiency responds to GLP-1 through the same receptor pathways as a woman with adequate estrogen levels.

The context in which GLP-1 acts is, however, estrogen sensitive in several clinically meaningful ways.

Lean mass preservation. GLP-1 driven weight loss, like any significant caloric deficit, comes with some reduction in lean mass alongside fat loss. In estrogen replete women, muscle retention during weight loss is meaningfully better, because estrogen supports satellite cell function and muscle protein synthesis. Without adequate estrogen, the same weight loss produces more sarcopenia alongside the fat reduction, and the composition of what is lost shifts unfavorably.

Insulin sensitivity. Estrogen improves insulin sensitivity through independent pathways. GLP-1 also improves insulin sensitivity, primarily by stimulating insulin secretion in proportion to prevailing blood glucose levels and by reducing hepatic glucose production. In women whose insulin resistance was driven substantially by estrogen decline, both mechanisms operate simultaneously, and the effect appears to compound.

Fat distribution during loss. Estrogen favors fat deposition in gluteofemoral tissue over visceral tissue. When a woman is estrogen replete and in a GLP-1 driven caloric deficit, the fat that is preferentially mobilized tends to be visceral rather than subcutaneous, because estrogen has already shifted the regional fat distribution pattern. Visceral fat is the depot most directly linked to cardiovascular risk, insulin resistance, and the waist circumference change that most women find both clinically and cosmetically significant.

Sleep quality as metabolic background. HRT reliably improves sleep in women whose disruption was driven by vasomotor symptoms and cortisol dysregulation. Sleep quality is the background condition for effective weight management, since sleep deprivation elevates ghrelin, suppresses leptin, and promotes the same visceral fat deposition that estrogen decline accelerates. Women whose HRT has restored sleep are in substantially better position to respond to any weight management protocol.

The 2025 Mayo data captured the total weight difference. The mechanistic evidence suggests the quality of what is lost and preserved may differ even more substantially than the headline percentage implies, and that the combination produces a more favorable body composition shift than the scale alone shows.

Who the Combination Is Most Appropriate For

The combined protocol is not indicated for every woman in perimenopause. The profile where published evidence most supports it: HRT that has been stable for at least three months, with acute vasomotor symptoms and sleep disruption already addressed; continuing central adiposity or upward weight trajectory despite stable HRT; BMI of 30 or above, or 27 or above with at least one weight related comorbidity such as hypertension, dyslipidemia, or impaired fasting glucose; and metabolic markers including fasting glucose, triglycerides, or HbA1c trending in an adverse direction.

For women in this clinical profile, a conversation with a prescribing provider about adding GLP-1 to the existing HRT is evidence supported and clinically appropriate. Bringing the current HRT regimen including agent, dose, and delivery form, along with the most recent lab panel, allows the provider to build the weight management protocol around the hormonal foundation already in place rather than starting independently of it.

Coordinating Between HRT and GLP-1 Prescribers

When GLP-1 is prescribed by a weight management provider and HRT by a menopause specialist operating in a separate clinical setting, coordination between the two is straightforward and worth completing. The key elements are shared awareness of both medications, the current HRT regimen and its delivery form, a monitoring plan for weight trajectory and relevant metabolic or cardiovascular markers, and explicit confirmation that neither regimen is changed while the other is being established.

Most menopause specialists in 2026 are familiar with GLP-1 and do not object to the combination. Some prefer to see HRT stable for three or more months before adding anything new. The practical guidance is to establish one regimen before starting the other when possible, rather than adjusting both simultaneously in the same clinical window.

The Oral vs. Injectable Question for Women on HRT

For women on transdermal estrogen delivered by patch, gel, or spray, the delivery form question for GLP-1 is largely a matter of patient preference and provider protocol. Transdermal estrogen bypasses the gastrointestinal tract entirely, meaning GLP-1's effect on gastric emptying has no meaningful influence on estrogen absorption. Either GLP-1 delivery route is clinically reasonable in this setting.

For women on oral estrogen, the picture is more nuanced. GLP-1 delays gastric emptying, which could theoretically affect the absorption kinetics of oral estrogen preparations, though clinically significant interference has not been demonstrated in published data. More practically, most menopause specialists now prefer transdermal delivery over oral for reasons unrelated to GLP-1, including hepatic first pass metabolism and venous thromboembolism risk profile. If a woman is on oral estrogen and considering GLP-1, that is a reasonable moment to discuss whether transdermal HRT delivery would be a better long term fit for the hormone component as well.

Why Oral Microdose GLP-1 Often Fits This Clinical Situation

Women who have worked to establish a stable HRT regimen have typically done so through a process of gradual titration, dose adjustment, and monitoring. Their sleep is calibrated on HRT. Their mood and energy are calibrated on HRT. Gastrointestinal motility may also be influenced by estrogen, which affects gut transit time. Starting at a full injectable GLP-1 label dose on a fixed weekly titration schedule introduces a significant additional variable into a system that has recently achieved equilibrium.

Oral microdose GLP-1 starts below the injectable label dose and adjusts based on individual response rather than a predetermined schedule. For the woman whose HRT regimen is optimized and whose clinical goal is to add weight management without disturbing the stability she has built, this approach fits the moment well. The mechanism is identical at the receptor level, and the tolerability profile during initiation tends to be considerably gentler than a full injectable ramp starting from 0.25 mg semaglutide or 2.5 mg tirzepatide. Published observations in this population note that women on this combination tend to see more of their weight loss from the waist than from other depots, which aligns with the mechanistic picture outlined above.

What GLP-1 and HRT Each Do Not Replace

GLP-1 receptor agonists are not a treatment for menopause. Hormone replacement therapy is not a weight management intervention. The combined protocol is two distinct prescriptions operating simultaneously in the same patient, each addressing what the other cannot. GLP-1 will not relieve hot flashes, support bone mineral density, or address genitourinary symptoms. HRT will not drive meaningful weight loss without an additional intervention targeting appetite and caloric balance. Both require prescription, both require ongoing clinical monitoring, and both are more effective and safer when managed as a coordinated regimen rather than in parallel clinical silos.

The Bottom Line

The 2025 Mayo Clinic retrospective analysis is the clearest population level signal yet that combining GLP-1 with HRT produces better weight outcomes than GLP-1 alone, with a difference of 17.3% versus 14.2% body weight lost at 18 months. The mechanistic basis for this difference is coherent and well supported in the basic science literature: estrogen replete women preserve more lean mass during weight loss, experience compounding improvements in insulin sensitivity, and lose proportionally more visceral fat because estrogen has already shifted the fat distribution pattern in a favorable direction.

For women on stable HRT who have not seen the body composition changes they were seeking, adding GLP-1 is the evidence supported next step. Oral microdose protocols offer a gentler entry into that addition, with the same receptor level mechanism as injectable GLP-1 and a titration pace that does not require disrupting a hormonal regimen that took time to establish.